⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BNTX News
BioNTech SE American Depositary Share
Global Perfusion Systems Market to Register Incremental Growth at a CAGR of ~5% by 2034 | DelveInsight
globenewswire.com
MDT
LIVN
BSX
THC
AMGN
AZN
PFE
JNJ
MRNA
BMY
GILD
REGN
TEVA
CL
PG
KO
PEP
DIS
NVDA
GOOG
AMZN
MSFT
AAPL
TSLA
META
CRM
ADBE
NFLX
INTC
AMD
QCOM
CMCSA
T
VZ
IBM
ORCL
CSCO
ACN
HON
GE
BA
CAT
XOM
CVX
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
HD
MCD
SBUX
COST
WMT
TGT
LOW
CVS
UNH
CI
ETSY
ROKU
PYPL
MELI
EBAY
BABA
JD
PDD
NTES
BIDU
TM
SONY
SAP
AIR
ASML
BNTX
NVO
BP
FCX
BHP
RIO
VALE
NKE
LULU
UA
CROX
NOC
GD
LMT
RTX
AVGO
AMAT
LRCX
MU
NXPI
MRVL
SNPS
CDNS
VRTX
BIIB
LLY
ABBV
MRK
CHTR
CMG
SIRI
GEHC
GSK
SNY
MREO
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
globenewswire.com
BNTX
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
globenewswire.com
BNTX
FairJourney Bio Opens Cryo-EM Structural Biology Facility in San Diego
businesswire.com
PFE
BNTX
MRNA
DualityBio gibt Annahme des Zulassungsantrags für Trastuzumab Pamirtecan zur Behandlung von nicht resezierbarem oder metastasiertem HER2-positivem Brustkrebs bei erwachsenen Patienten durch die chinesische NMPA bekannt USA - Deutsch USA - English USA -
prnewswire.com
BNTX
DualityBio annonce l'acceptation par la NMPA chinoise de la demande d'autorisation de mise sur le marché du trastuzumab pamirtecan pour le traitement du cancer du sein HER2 positif non résécable ou métastatique chez l'adulte USA - Français USA - English
prnewswire.com
BNTX
DualityBio anuncia la aceptación de NMPA de China de su solicitud de licencia para productos biológicos USA - español USA - English USA - English
prnewswire.com
BNTX
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer USA - English USA - English
prnewswire.com
BNTX
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
globenewswire.com
BNTX
BMY
Feinstein Institutes 2026 Ross Prize awarded to Drs. Michel Sadelain and Carl H. June
businesswire.com
BNTX